CE-MS metabolic profiling of volume-restricted plasma samples from an acute mouse model for epileptic seizures to discover potentially involved metabolomic features by Segers, K.R.H. et al.
Contents lists available at ScienceDirect
Talanta
journal homepage: www.elsevier.com/locate/talanta
CE-MS metabolic profiling of volume-restricted plasma samples from an
acute mouse model for epileptic seizures to discover potentially involved
metabolomic features
Karen Segersa,b,#, Wei Zhangc,#, Najat Aourzb, Jana Bongaertsa,b, Sven Declercka,
Debby Mangelingsa, Thomas Hankemeierc, Dimitri De Bundelb, Yvan Vander Heydena,
Ilse Smoldersb, Rawi Ramautarc,1, Ann Van Eeckhautb,∗,1
a Department of Analytical Chemistry, Applied Chemometrics and Molecular Modelling, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
bDepartment of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Laarbeeklaan 103, 1090,
Brussels, Belgium
c Biomedical Microscale Analytics, Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University,
Einsteinweg 55, 2333, CC Leiden, the Netherlands







A B S T R A C T
Currently, a high variety of analytical techniques to perform metabolomics is available. One of these techniques
is capillary electrophoresis coupled to mass spectrometry (CE-MS), which has emerged as a rather strong ana-
lytical technique for profiling polar and charged compounds. This work aims to discover with CE-MS potential
metabolic consequences of evoked seizures in plasma by using a 6Hz acute corneal seizure mouse model. CE-MS
is an appealing technique because of its capability to handle very small sample volumes, such as the 10 μL
plasma samples obtained using capillary microsampling in this study. After liquid-liquid extraction, the samples
were analyzed with CE-MS using low-pH separation conditions, followed by data analysis and biomarker
identification. Both electrically induced seizures showed decreased values of methionine, lysine, glycine, phe-
nylalanine, citrulline, 3-methyladenine and histidine in mice plasma. However, a second provoked seizure, 13
days later, showed a less pronounced decrease of the mean concentrations of these plasma metabolites, de-
monstrated by higher fold change ratios. Other obtained markers that can be related to seizure activities based
on literature data, are isoleucine, serine, proline, tryptophan, alanine, arginine, valine and asparagine. Most
amino acids showed relatively stable plasma concentrations between the basal levels (Time point 1) and after the
13-day wash-out period (Time point 3), which suggests its effectiveness. Overall, this work clearly demonstrated
the possibility of profiling metabolite consequences related to seizure activities of an intrinsically low amount of
body fluid using CE-MS. It would be useful to investigate and validate, in the future, the known and unknown
metabolites in different animal models as well as in humans.
1. Introduction
Metabolomics has emerged as a valuable tool for diagnostic pur-
poses, to predict and monitor disease progression and to measure
therapy efficacy. Moreover, biomarker knowledge provides a deeper
understanding of ongoing disease mechanisms, to advance drug dis-
covery and development. Most metabolomic studies were executed by
analyzing changes in a single biological sample type, such as tissue,
urine, serum or plasma [1,2]. In this study, plasma metabolites were
investigated to gain improved knowledge on the metabolic con-
sequences of refractory seizures evoked in the acute 6 Hz corneal
model. An epileptic seizure is defined by the International League
Against Epilepsy (ILAE) as a transient occurrence of signs and/or
symptoms due to abnormal excessive or synchronous neuronal activity
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in the brain [3]. A disturbance in the balance between excitation and
inhibition in the brain indeed results in seizures. It is known that these
seizures will affect the metabolism [4]. Increased knowledge about
global metabolic hallmarks related to a seizure will lead to an improved
understanding of seizure pathophysiology and can reveal novel path-
ways to control and prevent seizures.
Metabolomics has already been used to investigate changes in the
metabolome after seizures [5] or the effect of anti-seizure drug treat-
ment [6] in patients. Most studies, however, focus on brain metabolites
by studying brain tissue of a chemo convulsive animal model [7–12].
One of these studies focuses on the participation of cysteine during a
seizure and treatment of epilepsy in a mouse model [7]. Another study
analyzed different brain regions by NMR spectroscopy, where they
found an overlap in changes of the metabolites lactate, succinate, γ-
aminobutyric acid (GABA), choline and taurine in hippocampal tissue
and cerebellum of rats [12]. A similar study identified 26 metabolites
which are differentiating between the normal group and the rats with a
status epilepticus [9]. However, tissue analysis is challenging because
of several analytical and technical issues [13]. Therefore, circulating
blood-based biomarkers are potentially interesting as plasma is more
easily accessible than, for instance, cerebrospinal fluid [10,14,15]. At
the moment, only a few studies make use of plasma metabolite profiling
in epilepsy by using an animal model. As for example the study of
Heischmann et al. [8], makes use of a kainic acid model of temporal
lobe epilepsy to compare the metabolite depletions found in hippo-
campal tissue with the observations in plasma. Only a small number of
similar metabolic consequences were observed in both matrices. The
major change in plasma, 48 h after a seizure, occurred for triacylgly-
cerols, diacylglycerols, phosphatidylcholines, vitamin D and their de-
rivatives.
Besides animal models, the metabolic consequences of epilepsy are
also studied in human samples. One example is the study of Detour
et al. [16], which analyzed hippocampal tissue of different patients
with temporal lobe epilepsy and divided the samples into groups based
on classification criteria by ILAE. Concentration variations of gluta-
mine, glutamate, aspartate, taurine and N-acetylaspartate were ob-
served in the hippocampus of the drug-resistant epilepsy patients. Be-
sides tissue, characterization of drug-resistant epilepsy was conducted
in serum samples. Increased values of 3-OH-butyrate, 2-OH-valerate, 2-
OH- butyrate, acetoacetate, acetone, acetate, choline, alanine, gluta-
mate and scyllo-inositol were observed in patients with epilepsy. Fur-
thermore, decreased levels of glucose, lactate and citrate were observed
in these patients [17]. Contradictory, in a study by Al Zweiri et al. [18],
which was conducted a few years earlier than the aforementioned
study, no prominent markers of responsiveness to drug treatment in
epilepsy could be found in serum. Comparable increased levels of glu-
tamate and decreased levels of citrate were observed, based on GC-MS
metabolomics [5], as obtained in the study of Murgia et al. [17]. Other
findings of this study were the elevated levels of lactate, glutamate and
butanoic acid and a reduction of cysteine, glutamine, palmitic acid,
linoleic acid, elaidic acid, trans-13-octadecnoic acid, stearic acid, as-
paragine and glyceraldehyde [5].
Compared to studies in patients, only a few animal studies make use
of blood to obtain metabolic profiles in search for markers relevant to
epilepsy. As a result of the increased importance of animal welfare
(refinement, reduction and replacement), it is not allowed to take more
than 20 μL mice blood in a serial sampling strategy [19–21]. Alternative
sampling techniques, such as volumetric absorptive microsampling
[21,22], dried blood spots [19,21,23] and capillary microsampling
[19,21] were developed for that purpose. Capillary microsampling has
some benefits compared to other microsampling techniques, such as a
shorter handling time of the animals, while the equipment for sampling
is less expensive than for dried blood spots [19]. In different pharma-
cokinetic studies, the capillary microsampling technique has already
been applied, resulting in robust and reliable outcomes [24–26].
However, these microsampling methods lead to the additional chal-
lenge of extracting useful information from small sample volumes.
Consequently, the interest in microscale analytical methods has in-
creased in recent years [27,28].
Capillary electrophoresis mass spectrometry (CE-MS) is an inter-
esting microscale technique suitable to profile polar and charged me-
tabolites in small sample volumes [2,27–29]. The relatively low number
of applications of CE-MS in biomarker discovery is related to re-
producibility and sensitivity issues, as well as the complexity of cou-
pling CE to MS [27]. However, in recent years the CE-MS interface has
substantially improved, resulting in an increased sensitivity [30–32].
Several studies have already shown the reliability and repeatability of
CE-MS for biomarker discovery [33,34]. Harada et al. [33] performed a
large scale cohort study, which profiled more than 8000 human plasma
samples with a coefficient of variation for peak areas below 30% for 80
metabolites. A more recent study of our research group [34], demon-
strated the suitability of CE-MS for plasma metabolomics by a simulated
omics study combined with two data-analysis tools to handle the data.
Drouin et al. [35] proposed the use of the effective mobility of com-
pounds, instead of the migration time, as a more robust migration
index. Their work resulted in a database with the effective mobilities of
compounds, which will enable a straightforward annotation of detected
features in a biological sample.
In the presented study, using an acute 6Hz corneal mouse model for
refractory seizures, plasma metabolic consequences for seizures were
observed in a CE-MS profile through multivariate data analysis. Plasma
samples were collected using capillary microsampling at four time
points, i.e. before and after the seizure, with a wash-out period of 13
days between the two evoked seizures. All samples were analyzed with
a CE-MS method previously developed in the laboratory [34]. Data
analysis was conducted by multivariate curve resolution alternating
least squares (MCR-ALS) as feature-selection technique, followed by
unsupervised and supervised analyses to indicate some possible bio-





CE-MS capillary electrophoresis mass spectrometry
FC fold change
GABA gamma-aminobutyric acid
ILAE International League Against Epilepsy
IS internal standard
KEGG Kyoto Encyclopedia of Genes and Genomes
LOF lack-of-fit
MCR-ALS multivariate curve resolution alternating least squares
NMR nuclear magnetic resonance
NO nitric oxide
PCA principal component analysis
PLS-DA partial least squares discriminant analysis
QC quality control
ROI region of interest
SVD single value decomposition
VIP variable importance in projection
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2. Material and methods
2.1. Acute 6Hz corneal seizure mouse model
All procedures were carried out according to the National Rules of
Animal Experiments (Directive 2010/63) and were approved by the
Ethical Committee for Animal Experiments of the Faculty of Medicine
and Pharmacy of the Vrije Universiteit Brussel, Belgium (no. 18-213-2).
Male NMRI mice, weighing between 38 and 50 g, were obtained from
Charles River Laboratories (Sulzfield, Germany) and habituated at least
one week at the animal house prior to the experiments. Animals were
kept under standard laboratory conditions with a 10/14 h dark/light
cycle, with water and food ad libitum. The night before the experi-
ments, the animals were transferred to the experimental room.
A 6Hz seizure model as described and applied by [36–39], was used.
Corneal stimulation (6Hz, 0.2 ms rectangle pulse width, 3 s duration)
by using corneal electrodes connected to a stimulator (ECT Unit 57,800,
Ugo-Basile, Italy), induces limbic seizures. The optimal current in-
tensity was determined in 6 animals that showed a seizure duration of
more than 20 s and was found to be 52 mA. Local anesthesia was ob-
tained by applying 0.5% xylocaine (AstraZeneca, Brussels, Belgium) in
saline on the eyes before stimulating. These eye drops additionally re-
sult in good conductivity for the electrical stimulation. After stimula-
tion, the animals were placed in an open plastic box to observe the
presence or absence of a seizure. Seizures were characterized by a
stunned or fixed posture, forelimb clonus and elevated Straub-tail. The
seizure durations were manually recorded for each animal.
2.2. Sample collection
Blood samples of all animals (n = 8) were obtained with capillary
microsampling before and after each seizure on the first and the second
experimental day. In between both experimental days, a 13-day wash-
out period was applied. In this period the animals were kept under
standard laboratory conditions, as aforementioned, and without ma-
nipulations. On the first experimental day, the animals received an
injection of saline/propylene glycol (50/50 (V/V)) 15 min before the
corneal stimulation. On the second experimental day, the animals were
injected with a saline solution, 45 min before the corneal stimulation.
The difference in vehicle and time point of injection before the corneal
stimulation between the two days of experiments is due to the solubility
and half-life time of the administered drug in the treated group. On the
first day of experiments the treated group received carbamazepine and
on the second experimental day the animals received levetiracetam.
However, the samples of the treated groups were not analyzed, as the
animals were found not to be drug-resistant (i.e. there were not enough
mice that lacked anticonvulsant effects of carbamazepine and levetir-
acetam), although this was the primary research goal. Therefore, we
only included the non-treated animals and solely looked at the meta-
bolic consequences of the provoked seizure. An illustration of the an-
imal experiments with blood sampling time points (1–4) is shown in
Fig. 1. Blood was collected using capillary microsampling from the vena
saphena [24]. Additional blood was taken from the heart when the
animals were sacrificed after the second experimental day. All blood
samples were collected into EDTA-coated 32 μL capillaries (Virtex
Medical, Herlev, Denmark) and plugged 3 times with wax (sealing wax
plate, Hirschmann, Eberstadt, Germany). The waxed capillaries were
transferred to individually pre-labeled 5 mL Falcon® tubes (Corning,
Tewksbury, Massachusetts, United States) on ice prior to centrifugation.
The capillaries were centrifuged in a precooled centrifuge (4 °C) for
10 min at 1500 g. After centrifugation the capillaries were snapped
above the cell layer plug and exactly 10 μL of plasma was end-to-end
transferred to 10 μL capillaries (Virtex Medical, Herlev, Denmark) and
stored in labeled Cryo. S vials (Greiner Bio-One, Frickenhausen, Ger-
many). Blood from the heart was collected into EDTA coated tubes
(Vacutest, Azergrande, Italy) and centrifuged as previously explained.
The plasma layer was transferred to a labeled Eppendorf® tube (Ep-
pendorf, Hamburg, Germany). All plasma samples were stored at
−80 °C till sample preparation.
2.3. Quality control samples
The heart plasma samples of all animals were pooled, 10 μL of these
pooled samples was transferred into capillaries in Cryo. S vials (Greiner
Bio-One, Frickenhausen, Germany) and pretreated as the other plasma
samples of the four different time points.
The day of the analysis, samples were reconstituted in 25 μL water.
From each sample (time point 1–4 and the aliquots of the pooled heart
samples), 5 μL was taken to generate a pool of them, thereby obtaining
quality control (QC) samples to check for and to evaluate system var-
iations. The remaining 20 μL of the samples (time point 1–4 and the
aliquots of the pooled heart samples) was used for CE-MS analysis.
The suitability of the CE-MS method for human plasma samples was
already demonstrated in [34], but the composition and volume of
human plasma is different than that of mice. In order to investigate the
effect of capillary microsampling on the sample preparation, 10 μL
Fig. 1. Illustration of the experimental protocol. On
the first day, blood samples were collected before
given a vehicle to the animals (time point 1). Later, a
6Hz stimulation is given, followed by scoring the
seizure duration. After the seizure, a second blood
sample was collected (time point 2). After a 13-days
wash-out period the same experiment was repeated
(time point 3 and 4). In total, 4 blood samples were
collected: 1 before and 1 after the provoked seizure
on both experimental days (n = 8).
K. Segers, et al. Talanta 217 (2020) 121107
3
mouse plasma samples was spiked with four labeled compounds (i.e. L-
Alanine-13C2, L-Glutamine-13C2, L-Lysine-13C6, and L-Iso-
leucine-13C,15N) (Cambridge Isotope Laboratories, Apeldoorn, The
Netherlands) at a series of concentrations based on the naturally ex-
isting endogenous levels [40]. Moreover, the samples spiked with in-
termediate concentration levels were prepared in 8 replicates to
monitor the variation in the peak area (precision) and estimated con-
centration (accuracy).
2.4. Sample pretreatment
Plasma samples were prepared as described in [34]. To 10 μL stored
plasma samples, 250 μL Milli-Q water (Millipore, Amsterdam-Zuidoost,
the Netherlands), 250 μL methanol (HPLC grade, Actu-All Chemicals,
Oss, the Netherlands), 250 μL chloroform (HPLC grade, Biosolve Che-
micals, Valkensweerd, the Netherlands) and 20 μL 30 μM internal
standard (IS, prepared in Milli-Q water), i.e. DL-methionine sulfone
(Human Metabolome Technologies, Leiden, The Netherlands), were
added and vortexed followed by centrifugation at 2196g at 4 °C for
10 min. The supernatant (500 μL) was transferred to centrifugal filters
of 5 kDa (Millipore) and centrifuged for 1.5 h at 12000 g 300 μL of the
filtrate was transferred after centrifugation and evaporated under va-
cuum in a CentriVap Concentrator (Labconco). The dried residues were
stored at −80 °C prior to analysis.
2.5. Metabolic profiling by CE-MS
The same instruments and analytical methods as in [34] were used.
The analysis was conducted on an Agilent 7100 CE instrument hyphe-
nated to an Agilent 6230 Time of Flight mass spectrometer (Agilent
Technologies, Santa Clara, California) with a co-axial sheath-liquid in-
terface for the ESI source. The sheath liquid was a mixture of iso-
propanol/water (1:1, V/V), containing 0.2% acetic acid and was de-
livered at 5 μL/min. Separation was performed in a fused-silica
capillary (BGB Analytik (Harderwijk, The Netherlands)) of 70 cm
length and an internal diameter of 50 μm, which was thermostated at
22 °C. Milli-Q water containing 10% (V/V) acetic acid (99–100%)
(VWR, Amsterdam, The Netherlands) was used as background electro-
lyte (BGE). The samples were stored in the sample tray at 10 °C and
injected hydrodynamically at 50 mbar for 20 s. Electrophoretic se-
paration was achieved by applying a voltage of 30 kV and the MS de-
tection was done in positive mode. The MS parameter drying gas flow
rate was set at 11 L/min and the temperature was 100 °C. Additionally,
the nebulizer gas was set at 0 psi. Full scan acquisition, covering the
mass range of 50–1000 m/z, was conducted at 1.5 spectra s−1 acqui-
sition rate in centroid mode. Between analyses, the capillary was rinsed
as follows: water for 30 s at 5 bar, methanol for 1 min at 5 bar, water for
30 s at 5 bar, 10% ammonium hydroxide for 1 min at 5 bar, water for
30 s at 5 bar and BGE for 2 min at 5 bar.
2.6. Data processing
The obtained data were stored as. d files and converted to mzXML
formats with ProteoWizard (Palo Alto, California). These files were
imported and further analyzed in MatlabTM R2014a (The Mathworks,
Natick, MA), as described in [34].
First, a binning method was performed and data were compressed
through the detection of regions of interest (ROI) [41,42]. ROI values
were searched for each migration time in the CE-MS profile. However,
each ROI is defined by a signal threshold, mass accuracy and the
minimum time interval to be considered as peak width [43,44]. In our
study, the parameters are based on the protocol by Gorrochategui et al.
[44] and were set at 1000 for the signal threshold, 0.01 atomic mass
unites/e was used as mass accuracy and 6 s as the minimum time in-
terval.
After the ROI search in the metabolic profiles, feature detection was
performed with the MCR-ALS toolbox [45]. MCR-ALS does not require
peak alignment, which makes it very suitable for CE data, where sig-
nificant migration time shifts are typically observed [43]. The number
of components in the samples is initially guessed. The Single Value
Decomposition (SVD) method is the most suitable to resolve features.
Different SVD-numbers in an MCR-ALS model were evaluated, con-
sidering the explained variance and the lack-of-fit (LOF) error of the
model. To detect the purest variables, a 10% noise level threshold was
used. The features were detected by the best MCR-ALS model, con-
taining the highest explained variance and the lowest LOF error, were
then further investigated.
Considering that the peak area calculation by MCR-ALS was not
ideal, the obtained features were further investigated in the Data
Acquisition module within the MassHunter Workstation (Agilent, Santa
Clara, CA), which results in a proper integration of the detected fea-
tures. The result is a peak table containing areas of the obtained fea-
tures in all samples. After integration with the MassHunter Data ac-
quisition module, the peak areas of the integrated features were
normalized with that of the internal standard and then auto-scaled prior
to further statistical analysis.
2.6.1. Multivariate analysis
The normalized and auto-scaled data were visualized with ex-
ploratory unsupervised analysis techniques, such as clustering analysis
(complete linkage) and principal component analysis (PCA). PLS-DA
was performed as supervised classification technique to link the sample
time point with the obtained fingerprint. The numbers of latent vari-
ables for the models of the supervised analyses were chosen based on a
five-fold venetian-blind cross validation. Subsequently, a model was
evaluated based on the error rate, non-error rate and accuracy on the
cross-validation and calibration results. In the end, possible seizure
biomarkers are reported based on a VIP score above 1.0, which reflects
the importance of the variable in the discrimination between the groups
of interest, i.e. before and after a seizure.
2.6.2. Univariate analysis and fold change analysis
A pair-wise comparison was performed on the normalized data to
investigate the differences between the time points within and between
days, illustrated in Fig. 1. The animals were their own controls, which
allowed performing a paired samples test. Since the normal distribution
pattern of the differences could not be verified due to the small sample
size (n = 8), the non-parametric signed-rank or paired-samples Wil-
coxon test was used.
Besides the statistical p-value also fold changes (FC) are calculated
to demonstrate the strength of the increase (> 1) or decrease (< 1) of a
metabolite in plasma. Those FC values can be compared between both
evoked seizures. Additionally, the effectiveness of the wash-out period
can be shown by a FC of approximately 1. FC are calculated for the
comparison of time point 2 with 1 (FC2/1), time point 4 with 3 (FC4/3)
and time point 3 with 1 (FC3/1). The calculations are performed as
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3. Results and discussion
3.1. Evaluation of analytical workflow for metabolic profiling of volume-
restricted plasma samples
When performing metabolic profiling of volume-restricted samples,
aspects like sampling, sample preparation and analysis by CE-MS need
to be carefully evaluated in order to minimize technical variations.
Therefore, we have first assessed whether the plasma sampling tech-
nique had an effect on the CE-MS results. For this purpose, plasma
samples (n = 8) were spiked with four labeled compounds at con-
centrations reflecting the endogenous levels of the natural counterparts
in plasma. Those samples were then stored in 10 μL capillaries, as the
actual samples. The relative standard deviations (RSD) obtained for the
peak areas of these compounds were below 7.4%. The accuracy was
also investigated by comparing the spiked with the experimental con-
centrations. The results for the accuracy test fall in an acceptable range,
i.e. between 85 and 115% (data not shown).
Before starting the main analysis, one QC sample was analyzed ten
times to examine the repeatability of the CE-MS method. After ob-
taining a signal, repeatable in profile and intensity, the actual samples
were analyzed randomly and alternated with blank solutions and QC
samples (total number of QC samples = 13) and at the end some me-
tabolite standards (including the following compounds: glycine, L-ala-
nine, cytosine, proline, valine, homoserine, threonine, creatine, iso-
leucine, leucine, asparagine, adenine, anthranilic acid, tyramine,
spermidine, glutamine, lysine, glutamic acid, methionine, histidine,
phenylalanine, spermine, tryptophan, cytidine, adenosine), which can
be used for identification. The analysis of the QC samples will reflect
the system variation. As described in literature, to be reliable, RSD
values for the resolved features have to be below 30% for the AUC
values and below 5% for the migration times [46]. In this study, 44
measured m/z values in the QC samples showed acceptable RSD values
(below 20.3% for the corrected areas and below 2.5% for the migration
times). Two representative extracted ion electropherograms for the
reliable features (44) detected in a QC sample are shown in Fig. 2. A
drift correction was not performed because the instrumental drift was
negligible compared to the biological variation.
The variation in sample preparation was verified with the pooled
heart plasma sample, which was divided in 10 μL aliquots undergoing
the sample pretreatment. The RSD for all features taken into account
measured in the heart plasma samples were below 19.5% and 0.7% for
the corrected areas and migration times, respectively. The repeatability
of injection was examined by injecting the samples of the fourth time
point twice, resulting in RSD values between the two injections below
20.2% and 3.5% for the corrected areas and migration times, respec-
tively.
Summarized, all estimated variations were within the acceptance
limits, which demonstrates the reliability of the CE-MS method and
sampling technique to investigate the metabolites in volume-restricted
plasma samples.
3.2. Metabolic profiling of plasma samples from a mouse model for epileptic
seizures
The focus of this paper is to investigate the applicability of the
previously mentioned CE-MS method to detect plasma metabolites re-
lated to metabolic consequences for an evoked seizure. In total, 74
samples were analyzed, including 32 from the epileptic mouse model, 8
mouse heart samples, 8 samples from the 4th time point injected a
second time, 7 blank solutions, 6 standards, and 13 quality controls
which were injected between the different groups ad random. Data
compression resulted in 161 resolved m/z values. All m/z values were
manually evaluated to exclude spikes. Spikes can be the result of
electrical disturbance occurring in the MS system and are not related to
a metabolite. The feature detection allowed to reduce the data to 57 m/
z values with good predictive ability of the resulting MCR-ALS model;
i.e. 99.2% explained variance and 9.2% LOF error. However, this data
set also contains m/z values with an RSD above 30% for their peak area
ratios and of more than 5% for the migration times. After removing
these non-compliant features, 44 m/z values remained, which have
acceptable variations for migration times and corrected peak areas
measured for the QC samples, i.e. 2.5% and 20.3%, respectively.
Besides the non-parametric Wilcoxon test and fold change investiga-
tions, multivariate analysis was performed on these 44 features after
applying auto-scaling to eliminate the dominance of highly abundant
features.
First, the sample similarity was investigated by constructing a
dendrogram as shown in Fig. 3. This dendrogram was constructed using
the complete linkage method and the Euclidean distance as similarity
parameter. The further the samples are located from each other on the
X-axis, the more dissimilar. Three clusters are clearly revealed in the
dendrogram. The left group contains all samples after the first seizure
(i.e. Time point 2), illustrating high similarities between these profiles
and a clear distinction from all other time points. Notably, sample 23
from Time point 3 (i.e. after the wash-out period) is also present in this
cluster. The possible reason for similarity of sample 23 with these
cluster profiles may be related to the short seizure duration of the an-
imal (22 s).
Only three samples after the second seizure (Time point 4) are
clustering together with samples after the first seizure (Time point 2) in
the left cluster, which can be attributed to similar seizure durations for
both onsets. The mean durations of the first and second evoked seizures
were 3 min 2 s and 1 min 23 s, respectively. However, five samples after
the second seizure (Time point 4) are more similar with Time point 1
and 3. These five animals showed a decreased seizure duration com-
pared to the first seizure, which might result in a profile that is more
comparable to these at time point 1 and 3. From this clustering
Fig. 2. Reconstructed extracted ion electropherograms of the 44 reliable features (m/z values) in a QC sample as obtained by CE-MS.
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information, no clear distinction is observed between the first and third-
time point profiles, suggesting the effectiveness of the wash-out period.
The analogies at different time points and the related markers are
studied in more detail by PCA and in the statistical analysis.
The main objective was to find metabolic consequences of evoked
seizures in plasma. For that purpose profiles at time points 1 and 2, and
at time points 3 and 4 were compared. The overall clustering can be
seen in Fig. 4A. Here, a clear discrimination between the first sampling
time point in the naïve mice with the sample after a seizure can be
observed. Clustering tendency of the samples before and after a seizure
on the two experimental days is shown in PCA score plots (Fig. 4B and
C). For the first experimental day, the samples before a seizure (re-
presented by black dots in Fig. 4B) are clearly discriminated from those
after a seizure (represented by pink squares in Fig. 4B), suggesting a
dissimilar profile and changes that occurred by an evoked seizure. The
assessment on VIP scores led to the indication of 21 potential markers,
which were all statistically significant (p < 0.05) by univariate sta-
tistics (non-parametric paired-samples Wilcoxon test). The VIP scores
resulted from a PLS-DA model with 1 latent variable having good
predictive abilities (100% accuracy and non-error rate for both cali-
bration and cross-validation). Only 17 markers, shown in Table 1, could
be identified with an in-house standard mixture of Drouin et al. [35],
containing more than 450 compounds, and by applying the ROMANCE
software to calculate the effective electrophoretic mobilities [47]. This
annotation resulted in identified metabolites with the annotation of at
least two independent and orthogonal properties, i.e. accurate mass and
electrophoretic mobility. Features, which could not be annotated by the
in-house library, were annotated by the METLIN database [48]. This
approach resulted in too many metabolite options with a high level of
uncertainty and therefore these annotations were not included in the
table. In general, mass errors were below 16 ppm, which is acceptable
as the acceptance limit was set at 20 ppm [49]. Only one identified
metabolite, i.e. tryptophan (Table 3), has a mass error of 23.2 ppm and
the mobility variation is also higher than the acceptance limit of 10%
[35].
All metabolites in Table 1 were decreased in concentration after a
seizure, as demonstrated by Fig. 5, which contains concentration trends
and FC ratios of some identified amino acids of Table 1. Decreased
concentrations of isoleucine, serine, citrulline, histidine and proline
after a seizure are demonstrated by their FC < 1 and are also observed
in the study of Heischmann et al. [8]. These authors investigated me-
tabolite changes in rat plasma, 48 h after a seizure occurred in a chemo
convulsive model for seizures. The obtained FC ratios in our study are
similar to the ranges reported by Wang et al. [5] and Tan et al. [9] and
will indicate, when p < 0.05 and VIP-scores> 1, metabolites that
change due to metabolic consequences of a seizure.
When comparing the data files obtained before (represented by
green triangles in Fig. 4C) and after (represented by red diamonds in
Fig. 4C) the second evoked seizure, less dissimilarity is seen between
the samples after the 13-days wash-out period. This reduced dissim-
ilarity may be the result of the injected vehicle, which is different be-
tween the first (propylene glycol/saline (50/50 V/V)) and second ex-
perimental (saline) day, or due to the possibility that a second evoked
seizure will induce less metabolic consequences in plasma than a first.
However, this last consequence is in contradiction with “seizures beget
seizures”, but epilepsy and seizures are brain-specific disorders and
many compounds do not cross the blood-brain barrier [8]. Another
explanation could be related to the duration of the effects by an evoked
seizure. Therefore, this result may suggest the prolonged effect of a first
seizure reflected by the metabolite changes. The PLS-DA model resulted
in an accuracy of 88% for calibration and 63% for cross-validation re-
sults, suggesting less good predictive abilities of the model compared to
the previous PLS-DA model for the first day of experiments. Only four
metabolites were found statistically significant based on non-para-
metric univariate statistics, i.e. glutamate (FC4/3 = 1.09), glutamine
(FC4/3 = 1.11), 4-hydroxyproline (FC4/3 = 0.87) and methionine (FC4/
3 = 0.88). The latter two amino acids showed a decrease in plasma
concentration (FC4/3< 1) after the seizure, while glutamate and glu-
tamine plasma concentrations were increased (FC4/3> 1) in this study.
Glutamate was also increased in human serum samples in the studies of
Wang et al. [5] and Murgia et al. [17]. Additionally, in a chemo con-
vulsive rat model increased glutamate levels were also observed in
hippocampal tissue [9].
For both evoked seizures (1st and 2nd) some metabolites were in-
dicated by VIP-scores above 1. The amino acids lysine, glycine, phe-
nylalanine, methionine, citrulline and histidine showed for both
Fig. 3. Dendrogram of all samples (n = 32) (except the QC sample) to show similarities between the samples. Similarities are based on Euclidean distances,
calculated on the autoscaled X matrix.
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seizures a decrease in plasma concentrations (FC2/1 and FC4/3< 1), as
shown in Fig. 5. The less pronounced decrease for a second seizure is
additionally reflected by the higher value of the FC4/3 ratio on the
second day for the aforementioned metabolites compared to the FC2/1
ratio for the first seizure. A higher value for the FC ratio (which is still
below 1) means a lower decrease in plasma levels. For example, lysine
has on the first day a FC2/1 of 0.69 and for the second day the FC4/3 was
0.88. For the other amino acids, glycine, phenylalanine, methionine,
citrulline and histidine, the FC4/3 for the second seizure are 0.90, 0.90,
0.88, 0.85 and 0.92, respectively. From the univariate paired-samples
Wilcoxon-test the levels of all aforementioned amino acids are sig-
nificantly decreased (p < 0.05) for the first seizure, but after the
second seizure, significance is only obtained for methionine.
The decreased plasma concentration of proline after a seizure in the
6Hz mouse model is in contrast with the serum concentrations reported
in Ref. [5], which compared control groups with patients who had a
seizure within 48 h before sampling.
The lack of effectiveness of the wash-out period could be another
explanation to the less pronounced metabolic changes for a second
seizure. However, the similarities between time point 1 and 3 suggested
an effectiveness of the wash-out period. This similarity was demon-
strated by their clustering pattern in the PCA score plot (not shown).
Still, multivariate analyses revealed some responsible markers for the
distinction between the first seizure (Time point 2) and the post wash-
out period profiles (Time point 3), which are listed in Table 2.
Noteworthy, univariate results revealed that most (but not all) meta-
bolites with a VIP score above 1.0 were statistically different after the
wash-out period. Therefore, proper selection of a threshold for the VIP
score is important when using this parameter [50]. The threshold is
accordingly (study specific) often adjusted to values above 1 [51,52].
Thus, the VIP score allows to indicate potential biomarker candidates
without defining it as a biomarker [50]. In our study, the plasma levels
of glycine, serine, asparagine, threonine, methionine, alanine, 3-me-
thyladenine, citrulline, arginine, histidine, ornithine and lysine were
increased (13 days after the first seizure) compared to their post seizure
values. These increased values after the wash-out demonstrates the
influence of sampling time after a seizure, which may result in different
interpretations. Additionally, these increased levels, 13 days after the
seizure, reflect also the stabilization of the plasma levels during the
wash-out period. This stabilization is demonstrated by the concentra-
tion trends of some metabolites shown in Fig. 5 and by a FC3/1 of ap-
proximately 1, indicating that most metabolites are present at similar
concentration levels at both time points 1 and 3.
Another interesting aspect is the re-use of animals in an acute 6Hz
animal model. However, to our knowledge, nothing is currently known
about the similarity of the metabolite profiles over the different sei-
zures. Therefore, the comparison between the second and fourth time
point is made in Fig. 6. A clear discrimination of the samples belonging
to the first and second evoked seizure is demonstrated by this score
plot, suggesting a difference in metabolic consequences observed in
Fig. 4. PC1-PC2 score plot for the X matrix to compare the experimental time points (A) all investigated samples before and after an evoked seizure using internal
standard correction and auto-scaling as data pretreatment (B) the first experimental day (C) the second experimental day. Time point 1 is represented by dots (.), time
point 2 by squares (□), time point 3 is represented triangles (∆) and time point 4 by diamonds (◊).
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plasma for a second evoked seizure compared to a first. VIP score in-
vestigation resulted in the suggestion of 20 markers, of which 15 could
be identified (see Table 3). However, the identification of tryptophan is
not within the limits of mass error (23.2 ppm, where the limit is
20 ppm) [49] and of difference in mobility (12.4%, with limit 10%)
[35]. Although identification parameters are just outside the accep-
tance limits, tryptophan is further discussed in the biological inter-
pretation part. Higher plasma levels after the second seizure than after
Table 1
Markers, with their mass error (Δ ppm) and mobility error (Δ %mobility), obtained after the first provoked seizure, based on a variable importance in projection (VIP)
score above 1 and p-value below 0.05.
Compound [M+H]+ Δ ppm Migration time (min) Δ % mobility p-valueb VIP score Plasma concentrationc
Methionine 150.058 6.2 12.4 1 0.0078 1.5 Decreased
Unknown 148.115 – 7.5 – 0.0078 1.5
Lysine 147.113 3.9 7.1 0 0.0078 1.5
Glycine 76.040 6.1 9.4 0 0.0078 1.5
Alanine 90.055 3.2 10.1 0 0.0078 1.4
Unknown 136.096 – 9.5 – 0.0078 1.4
Arginine 175.118 1.3 7.4 2 0.0078 1.3
Threonine 120.065 4.2 12.2 1 0.0078 1.3
3-methyladenine 150.111 15.8 12.5 7 0.0234 1.3
Unknown 176.121 – 7.5 – 0.0006 1.3
Leucine/Isoleucinea 132.101 5.2 11.5 0 0.0078 1.3
Serine 106.050 4.9 11.7 0 0.0078 1.3
Asparagine 133.060 8.7 12.3 1 0.0078 1.2
Citrulline 176.102 4.2 12.6 1 0.0078 1.2
Unknown 172.092 – 10.5 – 0.0078 1.2
Unknown 119.093 – 11.5 – 0.0078 1.2
Phenylalanine 166.085 4.5 12.8 1 0.0078 1.2
Ornithine 133.100 1.5 7.1 1 0.0078 1.2
Valine 118.086 6.7 11.3 1 0.0078 1.2
Histidine 156.076 4.3 7.5 1 0.0078 1.1
Proline 116.070 7.5 13.2 1 0.0391 1.0
a Compounds present in the standard mixture, but not baseline separated.
b p-value from a non-parametric signed-rank Wilcoxon test.
c Compared to the basal levels.
Fig. 5. Concentration trends, between the different investigated time points, of some identified amino acids with their fold change (FC).
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the first were obtained for arginine, threonine, alanine, methionine,
glycine, asparagine, 3-methyladenine and citrulline as shown in Fig. 5.
For glycine, methionine and citrulline higher FC for the second day
(FC4/3) were found as already discussed above. The other amino acids,
arginine, threonine, alanine, asparagine and 3-methyladenine had a
FC4/3 of 0.89, 0.97, 0.96, 1.00 and 0.96, respectively. All these FC4/3
ratios for the second seizure are higher than the equivalent FC2/1, which
are 0.64, 0.74, 0.70, 0.71 and 0.74, shown for some metabolites in
Fig. 5. Our results demonstrate that a second seizure with the same
stimulation may result in a less pronounced decrease of the metabolite
levels in mouse plasma, compared to the decrease observed after the
first evoked seizure, which can also be seen in the concentration trend
profiles of Fig. 5 and the FC ratios (FC 2/1, FC4/3 and FC3/1).
3.3. Biological significance of the obtained findings
Pathway analysis with the Kyoto Encyclopedia of Genes and
Genomes (KEGG) software assigned most of the identified compounds
to the nucleotide and amino acid metabolism. The identified markers,
most of which are amino acids, play important roles in maintaining the
equilibrium between inhibitory and excitatory processes.
A seizure is the result of an imbalance between excitation and in-
hibition. The most important excitatory neurotransmitter is glutamate.
Most of the identified compounds in our work are directly or indirectly
related to glutamate, which shows elevated levels in our study after a
second seizure and in serum and extracellular brain tissues in other
publications [53–56]. A precursor of glutamate is glutamine, and a
decreased metabolization of glutamate to glutamine causes glutamate
accumulation resulting in a seizure [56–58]. This decreased values of
glutamine are obtained in plasma samples of a chemo convulsive rat
model [8] and in human serum samples [5] and are in contradiction
with the increased values observed in our study after a second evoked
seizure and in hippocampal sclerosis samples of humans in [16]. Other
metabolites indirectly involved in the glutamate-glutamine cycle in-
clude alanine, asparagine and leucine [59,60], which are all decreased
in our observations after an evoked seizure. This decrease in asparagine
is also described by Wang et al. [5] in human serum samples. The de-
creased plasma level of alanine is also observed in human hippocampal
sclerosis tissue [16].
Besides an increase in glutamate, the role of norepinephrine, epi-
nephrine, dopamine and serotonin is not fully clarified. A decrease of
these monoamines has been reported in epileptic seizures [59,61,62],
but in other scientific reports increased levels are described [63].
Therefore, a decrease in the precursors of those neurotransmitters, such
as tryptophan, phenylalanine and tyrosine, is expected after a seizure
[56,60,64] and demonstrated by our findings. This decrease of the
Table 2
Markers, with their mass error (Δ ppm) and mobility error (Δ %mobility), that are different after a seizure (Time point 2) and the recuperation period of 13 days
(Time point 3), based on a VIP score above 1.
Compound [M+H]+ Δ ppm Migration time (min) Δ % mobility p-valueb VIP score Plasma concentrationc
Glycine 76.040 6.1 9.4 0 0.0078 1.6 Increased
Unknown 136.096 – 9.5 – 0.0078 1.6
Serine 106.050 4.9 11.7 0 0.0078 1.5
Asparagine 133.060 8.7 12.3 1 0.0078 1.5
Threonine 120.065 4.2 12.2 1 0.0078 1.4
Methionine 150.058 6.2 12.4 1 0.0156 1.4
Alanine 90.055 3.2 10.1 0 0.0156 1.4
Creatine 132.076 2.2 9.3 1 0.0078 1.4 Decreased
Unknown 172.092 – 10.5 – 0.0234 1.3 Increased
3-methyladenine 150.111 15.8 7.74 7 0.0234 1.3
Citrulline 176.102 4.2 12.6 1 0.0156 1.3
Arginine 175.118 1.3 7.4 2 0.0156 1.3
Unknown 176.121 – 7.5 – 0.1215d 1.3
Histidine 156.076 4.3 7.5 1 0.0156 1.3
Ornithine 133.100 1.5 7.1 1 0.0234 1.3
Phenylalanine 166.085 4.5 12.8 1 0.0547d 1.2
Lysine 147.113 3.9 7.1 0 0.0391 1.2
Unknown 132.065 – 9.5 – 0.0078 1.2 Decreased
Unknown 148.115 – 7.5 – 0.0781d 1.1 Increased
Leucine/Isoleucinea 132.101 5.2 11.5 0 0.1799d 1.1
Tyrosine 182.083 10 13.0 1 0.0781d 1.0
Unknown 104.114 – 6.5 – 0.1094d 1.0 Decreased
Unknown 119.093 – 11.5 – 0.1484d 1.0 Increased
a Compounds present in the standard mixture, but not baseline separated.
b p-value from a non-parametric signed-rank Wilcoxon test.
c Changes in plasma concentration between seizure and after the wash-out period (13 days after first seizure).
d Non-significant differences.
Fig. 6. PC1-PC2 score plot for the X matrix to compare the profiles after two
different seizures using internal standard correction and autoscaling as data
pretreatment. Time point 2 is represented by green squares (□) and time point
4 by red diamonds (◊). (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
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precursor levels can be due to the decrease of the monoamines or due to
the overconsumption.
GABA is known as inhibitory neurotransmitter. Decreased GABA
levels can be found in neurodegenerative and epileptic disorders, as a
result of its use as an alternative energy source, instead of isoleucine
and valine [59]. Decreased values of these latter amino acids are ob-
served in our study and the decrease of valine is also described by
Detour et al. [16] in hippocampal tissue. Other metabolites, such as
glycine, serine, threonine [56,57,60,65], methionine [56,66], proline
[67], isoleucine, valine [59], arginine [68], creatine [56,60] and his-
tamine [69], are indirectly involved in a seizure.
In general, the mechanisms of all mentioned compounds are related
to brain activities. Therefore, the plasma concentrations should be in-
terpreted with care. The relation brain-plasma concentration depends
on the blood-brain barrier permeability of the compounds and may
additionally be influenced by specific transporters. For instance, a study
reported comparable glutamine concentrations in the hippocampus of
kindled and non-kindled rats [57], while lower glutamine concentra-
tions were reported in serum of patients with seizures [5]. In our study,
glutamine was identified as a marker for the second evoked seizure.
However, the number of similar metabolic changes in the hippocampus
and plasma is limited [8]. This is due to the fact that epilepsy and
seizures are brain related disorders, but there is an increased need for
peripheral markers as they allow a fast screening. The timing of the
experimental design, type of research samples may influence the out-
comes and even differences in analytical platforms can affect the find-
ings, but in general most of the identified metabolites show similarities
with other observations in literature.
4. Conclusion and future perspectives
In this study, we have demonstrated the utility of our approach,
which includes sampling, sample pretreatment and CE-MS analysis of
low-volume plasma samples, for finding metabolic consequences of
evoked seizures. Seizures were induced in mice by 6Hz corneal stimu-
lation and plasma samples were collected by capillary microsampling
before and after stimulation. The 6Hz electrical stimulation was re-
peated after a 13 days wash-out period to investigate whether the same
metabolic changes are observed in naive and previously stimulated
mice.
After both evoked seizures a decrease in plasma concentrations of
methionine, lysine, glycine, phenylalanine, 3-methyladenine, citrulline
and histidine is observed. The decreases of glycine, citrulline and his-
tidine are also observed in previously reported studies. However, in
general most amino acids showed a less pronounced decrease in plasma
after a second seizure compared to the first.
The reported decreased levels of isoleucine, serine, histidine, ci-
trulline, proline and tryptophan after a seizure are similar to observa-
tions in literature of a chemo convulsive animal model for seizures.
Therefore, these markers are related to some seizure activities and are
independent of the obtained seizure model. Additionally, the decreased
concentrations of alanine, arginine, valine and asparagine were also
previously observed in human hippocampal tissue studies or serum
samples. No significant differences between the basal plasma levels and
those obtained after a 13 days wash-out period were observed, sug-
gesting the effectiveness of the wash-out period.
Besides the similar observations of the previously described changes
in literature, some contradictions are present. As an example, the ob-
served changes of the monoamines and their precursors. Therefore, it
would be useful to further investigate and validate their role in different
animal models (electrical and chemo convulsive) as in humans by dif-
ferent analytical techniques. Additionally, some compounds were not
yet identified. Knowledge on their identity could define or clarify their
role in seizures.
In general, most metabolic markers that were identified by our
study are amino acids. This could be attributed to the employed CE-MS
separation conditions, which are specifically suited for the profiling of
basic metabolites, including compound classes, such as amino acids,
amines and nucleosides. A next step would be to use also CE-MS for the
profiling of acidic metabolites, i.e. organic acids, nucleotides and sugar
phosphates, in the same samples and to assess whether metabolic
changes can be detected which might be linked to seizures. For lipid-
like compounds, we would like to investigate the potential of non-
aqueous CE-MS in the future.
Overall, our study emphasized the suitability of CE-MS to analyze
volume-restricted plasma samples with an acceptable variation.
Table 3
Markers, with their mass error (Δ ppm) and mobility error (Δ %mobility), that are different after the two seizures, by comparing time point 4 with time point 2, based
on a VIP score above 1.0.
Compound [M+H]+ Δ ppm Migration time (min) Δ % mobility p-valuec VIP score Plasma concentrationd
Arginine 175.118 1.3 7.4 2 0.0078 1.7 Increased
Threonine 120.065 4.2 12.2 1 0.0078 1.6
Alanine 90.055 3.2 10.1 0 0.0078 1.6
Unknown 176.121 – 7.5 – 0.0756e 1.6
3-methyladenine 150.111 15.8 12.5 7 0.0078 1.5
Unknown 172.092 – 10.5 – 0.0078 1.5
Unknown 119.093 – 11.5 – 0.0156 1.4
Methionine 150.058 6.2 12.4 1 0.0078 1.4
Glycine 76.040 6.1 9.4 0 0.0078 1.4
Asparagine 133.060 8.7 12.3 1 0.0078 1.3
Unknown 136.096 – 9.5 – 0.0078 1.3
Ornithine 133.100 1.5 7.1 1 0.0781e 1.2
Phenylalanine 166.085 4.5 12.8 1 0.0547e 1.2
Proline 116.070 7.5 13.2 1 0.0547e 1.2
Leucine/Isoleucinea 132.101 5.2 11.5 0 0.0781e 1.2
L-acetylcarnitine 204.123 1 8.7 1 0.0391 1.1
Unknown 104.114 – 6.5 – 0.0391 1.1 Decreased
Valine 118.086 6.7 11.3 1 0.07813 1.1 Increased
Tryptophanb 205.081 23.2 12.4 12 0.0391 1.1
Citrulline 176.102 4.2 12.6 1 0.05473 1.1
a Compounds present in the standard mixture, but not baseline separated.
b Conflict of identification, due to too high mass error and mobility difference.
c p-value from a non-parametric signed-rank Wilcoxon test.
d Changes in plasma concentrations between first and second evoked seizure.
e Non-significant differences.
K. Segers, et al. Talanta 217 (2020) 121107
10
Additionally, the method is sensitive enough to measure a suitable
profile of polar components, differentiating the samples before and
after an evoked seizure and define some amino acids involved in evoked
seizures.
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